Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds

Details for Australian Patent Application No. 2010229711 (hide)

Owner Anthrogenesis Corporation

Inventors Zhang, Xiaokui; Kang, Lin; Heidaran, Mohammad; Jasko, Steven; Zeitlin, Andy; Pal, Ajai; Hariri, Robert J.

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-A-2010229711

PCT Pub. Number WO2010/111631

Priority 61/163,449 25.03.09 US

Filing date 26 March 2010

Wipo publication date 30 September 2010

International Classifications

C12N 5/0783 (2010.01) Undifferentiated human, animal or plant cells, e.g. cell lines - T cells

A61K 35/50 (2006.01) Medicinal preparations containing material or reaction products thereof with undetermined constitution

A61P 35/00 (2006.01) Antineoplastic agents

A61K 35/12 (2006.01) Medicinal preparations containing material or reaction products thereof with undetermined constitution - Materials from mammals or birds

Event Publications

27 October 2011 PCT application entered the National Phase

  PCT publication WO2010/111631 Priority application(s): WO2010/111631

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010229713-Antibody composition with altered Fab sialylation

2010229709-Cannula with integrated camera and illumination